Filing Flows › Pacific Biosciences of California (PACB) › Q2 2026 › vs Q2 2025
Pacific Biosciences of California (PACB) Q2 2026 vs Q2 2025 (year over year)
Pacific Biosciences of California's revenue fell $759K (-2%) from $39.8M in Q2 2025 to $39.0M in Q2 2026. The biggest changes: Service and other revenue −$626K (-9%); Product revenue −$133K (-0.4%).
Pacific Biosciences of California, Q2 2026: revenue $39.0M (-2% year over year), operating margin -114.4%, net loss $44.7M, operating cash flow −$35.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Consumable revenue | $20.1M | $18.9M | $1.2M | +6% |
| Instrument revenue | $12.8M | $14.2M | −$1.3M | -9% |
| Product revenue | $33.0M | $33.1M | −$133K | -0.4% |
| Service and other revenue | $6.1M | $6.7M | −$626K | -9% |
| Revenue | $39.0M | $39.8M | −$759K | -2% |
| Net loss | $44.7M | $41.9M | $2.8M | +7% |
| Costs & expenses | $83.7M | $84.7M | −$906K | -1% |
| Operating costs | $83.6M | $84.6M | −$1.0M | -1% |
| Income tax | $58K | $35K | $23K | +66% |
| Cost of revenue | $26.4M | $25.1M | $1.3M | +5% |
| Research & development | $23.0M | $22.5M | $493K | +2% |
| SG&A | $33.4M | $36.2M | −$2.8M | -8% |
| Other operating costs | $833K | $833K | $0 | 0% |
| Operating cash sources | $47.2M | $45.0M | $2.2M | +5% |
| Depreciation | $2.3M | $3.7M | −$1.4M | -37% |
| Share-based compensation | $9.3M | $11.9M | −$2.6M | -22% |
| Cash used in operations | $35.6M | $29.4M | $6.2M | +21% |
| Net loss absorbed | $44.7M | $41.9M | $2.8M | +7% |
| Working capital & other | $2.4M | $3.0M | −$594K | -20% |
Questions
How much did Pacific Biosciences of California's revenue grow year over year in Q2 2026?
Pacific Biosciences of California's revenue fell $759K (-2%) from $39.8M in Q2 2025 to $39.0M in Q2 2026.
What drove Pacific Biosciences of California's revenue change in Q2 2026?
Service and other revenue −$626K (-9%); Product revenue −$133K (-0.4%).